Mohan Viswanathan, Kalra Sanjay, Kesavadev Jothydev, Singh Awadhesh Kumar, Kumar Ajay, Unnikrishnan Ambika Gopalakrishnan, Chawla Rajeev, Mukherjee Jagat Jyoti, Sahay Rakesh Kumar, Kumar J S, Bhoraskar Anil, Asirvatham Arthur J, Panda Jayanta Kumar, Zargar Abdul Hamid, Das Ashok Kumar
Madras Diabetes Research Foundation and Dr Mohan's Diabetes Specialities Centre, Chennai, Tamil Nadu.
Bharti Research Institute of Diabetes and Endocrinology, Karnal, Haryana.
J Assoc Physicians India. 2017 Apr;65(4):59-73.
Premix insulin is the most commonly used insulin preparation in India. The first Indian premix guidelines were developed in 2009 and thereafter were updated in 2013. There is a need to revisit the Indian premix insulin guidelines, in view of emerging evidence and introduction of newer co-formulations.
The present consensus has been developed to evaluate available premix formulations, examine existing evidence related to premix formulations, and evolve consensus statement of recommendations on the topic.
A meeting of experts from across India was conducted at Chennai in July 2016. The expert committee evaluated each premix insulin regimen with reference to 1) Current recommendations by various guidelines, 2) Approved pack inserts and 3) Published scientific literature. The information was debated and discussed within the expert group committee, to arrive at seven consensus-based recommendations for initiation and intensification with premix insulin.
Recommendations based on consensus on initiation and intensification of premix insulin in type 2 diabetes mellitus (T2DM) management were developed for the following situations. 1) Initiation of premix insulin co-formulation at diagnosis, 2) Initiation of once daily (OD) premix insulin/co-formulation, 3) Initiation of twice daily (BID) premix insulin/co-formulation 4) Intensification with BID and thrice daily (TID) premix insulin/co-formulation. Three recommendations pertained to the use of premix insulin in other forms of diabetes, or in specific situations: 5) Use of premix insulin in gestational diabetes mellitus 6) Use of premix insulin in type 1 Diabetes Mellitus (T1DM) 7) Premix insulin use during Ramadan.
In the setting of high carbohydrate consumption in India, or in patients with predominant post prandial hyperglycemia, premix insulin/co-formulation can offer effective and convenient glycemic control. This paper will help healthcare practitioners initiate and intensify premix insulin effectively.
预混胰岛素是印度最常用的胰岛素制剂。印度首个预混胰岛素指南于2009年制定,之后在2013年进行了更新。鉴于新出现的证据以及新型复方制剂的引入,有必要重新审视印度预混胰岛素指南。
制定本共识以评估现有的预混制剂,审查与预混制剂相关的现有证据,并就该主题形成推荐的共识声明。
2016年7月在金奈召开了一次来自印度各地的专家会议。专家委员会参照以下内容对每种预混胰岛素方案进行了评估:1)各种指南的当前推荐;2)批准的药品说明书;3)已发表的科学文献。在专家小组委员会内部对这些信息进行了辩论和讨论,以得出关于预混胰岛素起始和强化治疗的七条基于共识的推荐意见。
针对以下情况制定了关于2型糖尿病(T2DM)管理中预混胰岛素起始和强化治疗的基于共识的推荐意见。1)诊断时起始预混胰岛素复方制剂;2)起始每日一次(OD)预混胰岛素/复方制剂;3)起始每日两次(BID)预混胰岛素/复方制剂;4)使用每日两次和每日三次(TID)预混胰岛素/复方制剂进行强化治疗。另外三条推荐意见涉及预混胰岛素在其他糖尿病形式或特定情况下的使用:5)在妊娠期糖尿病中使用预混胰岛素;6)在1型糖尿病(T1DM)中使用预混胰岛素;7)斋月期间使用预混胰岛素。
在印度高碳水化合物摄入的情况下,或在以餐后高血糖为主的患者中,预混胰岛素/复方制剂可提供有效且方便的血糖控制。本文将有助于医疗从业者有效地起始和强化预混胰岛素治疗。